Oncogene Panel Assay Development
Your Development. Our Platform.
The TessArae Oncogene Panel Assay was developed in collaboration with Galil Genetic Analysis Ltd. (GGA). The largest private genetic diagnostic testing lab in Israel, GGA specializes in oncogenetic predisposition testing. This assay simultaneously screens for the presence of 3,320 known mutations in 11 different genes associated with breast, colorectal, and other cancer types. See the number of mutations in each gene.
Partnering with TessArae accelerates your development of a turnkey Oncogene Assay that truly delivers.
Fast From extracted sample to a gene-by-gene, locus-by-locus list of detected mutations in less than 24 hours. TessArae enables the development of the fastest multiplexed sequencing assays available today.
Precise The DNA sequence is provided at each locus – indicating wildtype or mutant, and heterozygous or homozygous. Sophisticated confidence metrics give you the accuracy you need.
Comprehensive The assay generates full exon sequence – plus a portion of the 5’ and 3’ intronic sequence – for all 11 genes. This enables accurate detection of: (1) targeted single base mutations and polymorphisms; (2) targeted insertions and deletions; and (3) even novel single base mutations.
For more information about the GGA Oncogene Assay panel, please visit their website, www.gga.org.il.